SC
LCTX icon

SummitTX Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

SummitTX Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60,833
Closed -$96.1K – 912
2026
Q1 		$96.1K Buy
60,833
+39,514
+185% +$66.6K ﹤0.01% 715
2025
Q4 		$35.6K Sell
21,319
-52,516
-71% -$90.9K ﹤0.01% 671
2025
Q3 		$125K Sell
73,835
-212,685
-74% -$252K 0.01% 715
2025
Q2 		$260K Buy
+286,520
New +$170K 0.01% 645

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SummitTX Capital's LCTX Position: Q2 2026 in Review

SummitTX Capital sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 60,833 shares — an estimated $96.1K sold.

SummitTX Capital first reported a position in LCTX in Q2 2025 and held it in 4 quarters. The position peaked at $260K in Q2 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • SummitTX Capital reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SummitTX Capital sold 60,833 Lineage Cell Therapeutics shares in Q2 2026, an estimated $96.1K.
  • SummitTX Capital first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 4 quarters.
  • SummitTX Capital's Lineage Cell Therapeutics position peaked at $260K in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.